The European Medicines Agency is examining several new measures to improve the current poor predictability of initial marketing applications, such as increased transparency around companies who delay their submissions more than once.
The need for new, more vigorous measures was felt after an earlier initiative launched by the EMA to address the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?